proton pump inhibitor


Also found in: Dictionary, Thesaurus, Legal, Acronyms, Encyclopedia, Wikipedia.

inhibitor

 [in-hib´ĭ-tor]
1. any substance that interferes with a chemical reaction, growth, or other biologic activity.
2. a chemical substance that inhibits or checks the action of a tissue organizer or the growth of microorganisms.
3. an effector that reduces the catalytic activity of an enzyme.
ACE i's (angiotensin-converting enzyme i's) see angiotensin-converting enzyme inhibitors.
angiogenesis inhibitor a group of drugs that prevent growth of new blood vessels into a solid tumor.
aromatase i's a class of drugs that inhibit aromatase activity and thus block production of estrogens; used to treat breast cancer and endometriosis.
C1 inhibitor (C1 INH) a member of the serpin group, an inhibitor of C1, the initial component activated in the classical complement pathway. Deficiency of or defect in the protein causes hereditary angioedema.
carbonic anhydrase inhibitor an agent that inhibits the enzyme carbonic anhydrase; used in treatment of glaucoma and sometimes for epilepsy, familial periodic paralysis, acute mountain sickness, and kidney stones of uric acid.
cholinesterase inhibitor anticholinesterase.
COX-2 i's (cyclooxygenase-2 i's) a group of nonsteroidal antiinflammatory drugs that act by inhibiting cyclooxygenase-2 activity; they have fewer gastrointestinal side effects than other NSAIDs. Two members of the group are celecoxib and rofecoxib.
gastric acid pump inhibitor an agent that inhibits gastric acid secretion by blocking the action of H+,K+-ATPase at the secretory surface of gastric parietal cells; called also proton pump i.
HIV protease inhibitor any of a group of antiretroviral drugs active against the human immunodeficiency virus; they prevent protease-mediated cleavage of viral polyproteins, causing production of immature viral particles that are noninfective. Examples include indinavir sulfate, nelfinavir mesylate, ritonavir, and saquinavir.
HMG-CoA reductase i's a group of drugs that competitively inhibit the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis, and are used to lower plasma lipoprotein levels in the treatment of hyperlipoproteinemia. Called also statins.
membrane inhibitor of reactive lysis (MIRL) protectin.
monoamine oxidase inhibitor any of a group of drugs that inhibit the action of monoamine oxidase, the enzyme that breaks down norepinephrine and serotonin, prescribed for their antidepressant action; the most widely used ones are isocarboxazid, phenelzine, and tranylcypromine. They are also used in the prevention of migraine.
α2-plasmin inhibitor α2-antiplasmin.
plasminogen activator inhibitor (PAI) any of several regulators of the fibrinolytic system that act by binding to and inhibiting free plasminogen activator. Their concentration in plasma is normally low, but is altered in some disturbances of bodily hemostasis. PAI-1 is an important fast-reacting inhibitor of t-plasminogen activator and u-plasminogen activator. Its synthesis, activity, and release are highly regulated; elevated levels of it have been described in a number of disease states. PAI-2 is a normally minor inhibitor that greatly increases in concentration during pregnancy and in certain disorders. PAI-3 is protein C inhibitor.
platelet inhibitor any of a group of agents that inhibit the clotting activity of platelets; the most common ones are aspirin and dipyridamole. See also antiplatelet therapy.
protease inhibitor
1. a substance that blocks activity of endopeptidase (protease), such as in a virus.
protein C inhibitor the primary inhibitor of activated anticoagulant protein C; it is a glycoprotein of the serpin family of proteinase inhibitors and also inhibits several other proteins involved in coagulation (thrombin, kallikrein, and coagulation factors X and XI) and urokinase. Called also plasminogen activator inhibitor 3.
proton pump inhibitor gastric acid pump i.
reverse transcriptase inhibitor a substance that blocks activity of the reverse transcriptase of a retrovirus and is used as an antiretroviral agent. Some are nucleosides or nucleoside analogues, and those that are not are therefore often called non-nucleoside reverse transcriptase inhibitors.
selective serotonin reuptake inhibitor (SSRI) any of a group of drugs that inhibit the inactivation of serotonin by blocking its absorption in the central nervous system; used as antidepressants and in the treatment of obsessive-compulsive disorder and panic disorder.
serine protease inhibitor (serine proteinase inhibitor) serpin.
topoisomerase i's a class of antineoplastic agents that interfere with the arrangement of DNA in cells.

proton pump inhibitor

agents that block the transport of hydrogen ions into the stomach and hence are useful in the treatment of gastric hyperacidity.

proton pump inhibitor

n.
Any of a class of drugs that inhibit gastric acid secretion by interfering with the movement of hydrogen ions across cell membranes and are used mainly to treat peptic ulcers and gastroesophageal reflux disease.

proton pump inhibitor

an agent that inhibits gastric acid secretion by blocking the action of hydrogen ions, potassium ions, and adenosine triphosphatase at the secretory surface of gastric parietal cells. Also called gastric acid pump inhibitor.

proton pump inhibitor

An agent—e.g., Prilosec (omeprazole))—used to reduce gastric acid production in patients with dyspepsia, peptic ulcer disease, gastrooesophageal reflux disease, Barrett’s disease, and other conditions.

Adverse effects
Hip fracture, Clostridium difficile infection, hypomagnesaemia and acute interstial nephritis.

proton pump inhibitor

Pharmacology A compound–eg, Prilosec– omeprazole that is better than H2 blockers–eg, Zantac–ranitidine, Tagamet– cimetidine, for treating GERD. See Gastroesophageal reflux disease. Cf H2 blockers.

pro·ton pump in·hib·i·tor

(prō'ton pŭmp in-hib'i-tŏr)
An agent that blocks the transport of hydrogen ions into the stomach and henceis useful in the treatment of gastric hyperacidity, as observed in ulcer disease.

proton pump inhibitor

One of a class of drugs that interfere with the action of the proton pump responsible for the synthesis of hydrochloric acid in the parietal cells of the stomach lining. The proton pump is the enzyme H+, K+ -ATPase and this can be blocked by drugs such as OMEPRAZOLE (Losec).

Proton pump inhibitor

One of a group of drugs that acts to reduce the secretion of stomach acid.
Mentioned in: Cox-2 Inhibitors

pro·ton pump in·hib·i·tor

(prō'ton pŭmp in-hib'i-tŏr)
Agent that blocks transport of hydrogen ions into stomach and hence are useful in treatment of gastric hyperacidity.

proton

an elementary particle of mass number 1, with a positive charge equal to the negative charge of the electron; a constituent particle of every nucleus, the number of protons in the nucleus of each atom of a chemical element being indicated by its atomic number.

proton pump
see sodium pump.
proton pump inhibitor
a class of therapeutic agents which are used to counteract the effects of proton pumps in tissues and organs, particularly used in counteracting gastric hypersecretion and acidity.
References in periodicals archive ?
For patients who do not achieve satisfactory therapeutic effects by proton pump inhibitors, Pariet can be given orally at a dose of 10 mg or 20 mg twice-daily for additional 8 weeks.
Proton pump inhibitors for prophylaxis of nosocomial upper gastrointestinal tract bleeding effect of standardized guidelines on prescribing practice.
Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors.
The mineral deficit most frequently associated with proton pump inhibitor use is magnesium.
However, according to Heidelbaugh and co-authors (2012), in the non-ICU areas, 22-54% of patients were placed on proton pump inhibitors for ulcer prophylaxis and over one-half of these patients were discharged home on PPIs started in the hospital.
Proton pump inhibitor and protease inhibitor use are associated with fragility fracture risk in HIV-positive male veterans.
Using at random allocation 22 patients received standard proton pump inhibitor (group A) and 20 received herbal medicine (group B).
Proton pump inhibitor drugs have been found in observational research to seriously boost risk of illnesses ranging from kidney and cardiovascular disease to earlier mortality.
Major Finding: Use of proton pump inhibitors increased patient risk for diarrhea due to Clostridium difficile infection by 80%.
Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors.
Patients who used proton pump inhibitor drugs during this time were found to have a 38% increased risk of dementia, and a 44% increase in the risk of Alzheimer's, compared to those with no history of proton pump inhibitor use.